Paul Tudor Jones's BIIB Position Overview
Paul Tudor Jones (via Tudor Investment Corp Et Al) currently holds 26,088 shares of Biogen Inc. (BIIB) worth $5.89 M, representing 0.01% of the portfolio. First purchased in 2013-Q2, this long-term strategic position has been held for 47 quarters.
Based on 13F filings since 2013, Paul Tudor Jones has maintained a long-term strategic position in BIIB, representing a significant commitment to this investment thesis. Largest addition occurred in Q3 2016, adding 107,545 shares. Largest reduction occurred in Q4 2016, reducing 117,853 shares.
Analysis based on 13F filings available since 2013 Q2
Paul Tudor Jones's Biogen (BIIB) Holding Value Over Time
Track share changes against reported price movement
Quarterly Biogen (BIIB) Trades by Paul Tudor Jones
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q3 2026 | +26,088 | New Buy | 26,088 | $225.88 |
| Q3 2025 | -6,000 | Sold Out | 0 | $0.00 |
| Q2 2025 | -99,851 | Reduce 94.33% | 6,000 | $125.59 |
| Q1 2025 | +83,848 | Add 381.08% | 105,851 | $136.84 |
| Q4 2024 | -31,708 | Reduce 59.03% | 22,003 | $152.92 |
| Q3 2024 | +45,043 | Add 519.65% | 53,711 | $193.84 |
| Q2 2024 | -36,374 | Reduce 80.76% | 8,668 | $231.82 |
| Q1 2024 | +45,042 | New Buy | 45,042 | $215.63 |
| Q1 2023 | -4,995 | Sold Out | 0 | $0.00 |
| Q4 2022 | -4,548 | Reduce 47.66% | 4,995 | $0.28 |
| Q3 2022 | +7,810 | Add 450.66% | 9,543 | $267.00 |
| Q2 2022 | -3,259 | Reduce 65.28% | 1,733 | $203.69 |
| Q1 2022 | +4,992 | New Buy | 4,992 | $210.54 |
| Q4 2021 | -8,595 | Sold Out | 0 | $0.00 |
| Q3 2021 | +4,606 | Add 115.47% | 8,595 | $282.96 |
| Q2 2021 | +3,989 | New Buy | 3,989 | $346.20 |
| Q1 2021 | -3,438 | Sold Out | 0 | $0.00 |
| Q4 2020 | +3,438 | New Buy | 3,438 | $244.91 |
| Q3 2020 | -4,820 | Sold Out | 0 | $0.00 |
| Q2 2020 | +482 | Add 11.11% | 4,820 | $267.63 |
| Q1 2020 | +590 | Add 15.74% | 4,338 | $316.27 |
| Q4 2019 | -48,931 | Reduce 92.89% | 3,748 | $296.69 |
| Q3 2019 | +19,242 | Add 57.55% | 52,679 | $232.83 |
| Q2 2019 | -6,874 | Reduce 17.05% | 33,437 | $233.87 |
| Q1 2019 | +15,601 | Add 63.14% | 40,311 | $236.39 |
| Q4 2018 | +6,248 | Add 33.84% | 24,710 | $300.93 |
| Q3 2018 | +10,871 | Add 143.21% | 18,462 | $353.32 |
| Q2 2018 | +1,953 | Add 34.64% | 7,591 | $290.21 |
| Q1 2018 | +2,284 | Add 68.10% | 5,638 | $273.86 |
| Q4 2017 | +3,354 | New Buy | 3,354 | $318.43 |
| Q2 2017 | -1,752 | Sold Out | 0 | $0.00 |
| Q1 2017 | -6,063 | Reduce 77.58% | 1,752 | $273.40 |
| Q4 2016 | -117,853 | Reduce 93.78% | 7,815 | $283.56 |
| Q3 2016 | +107,545 | Add 593.42% | 125,668 | $313.03 |
| Q2 2016 | +17,123 | Add 1712.30% | 18,123 | $241.85 |
| Q1 2016 | -3,368 | Reduce 77.11% | 1,000 | $260.00 |
| Q4 2015 | +4,368 | New Buy | 4,368 | $306.32 |
| Q3 2015 | -600 | Sold Out | 0 | $0.00 |
| Q2 2015 | -4,280 | Reduce 87.70% | 600 | $403.33 |
| Q1 2015 | -22,906 | Reduce 82.44% | 4,880 | $422.34 |
| Q4 2014 | +24,725 | Add 807.74% | 27,786 | $339.45 |
| Q3 2014 | +2,162 | Add 240.49% | 3,061 | $330.94 |
| Q2 2014 | -2,400 | Reduce 72.75% | 899 | $314.79 |
| Q1 2014 | +1,532 | Add 86.70% | 3,299 | $305.85 |
| Q4 2013 | +267 | Add 17.80% | 1,767 | $279.57 |
| Q3 2013 | -2,300 | Reduce 60.53% | 1,500 | $240.67 |
| Q2 2013 | +3,800 | Add 0.00% | 3,800 | $215.26 |
Paul Tudor Jones's Biogen Investment FAQs
Paul Tudor Jones first purchased Biogen Inc. (BIIB) in Q2 2013, acquiring 3,800 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Paul Tudor Jones has held Biogen Inc. (BIIB) for 47 quarters since Q2 2013.
Paul Tudor Jones's largest addition to Biogen Inc. (BIIB) was in Q3 2016, adding 125,668 shares worth $39.34 M.
According to the latest 13F filing for Q3 2026, Paul Tudor Jones's firm, Tudor Investment Corp Et Al, owns 26,088 shares of Biogen Inc. (BIIB), valued at approximately $5.89 M.
As of the Q3 2026 filing, Biogen Inc. (BIIB) represents approximately 0.01% of Paul Tudor Jones's publicly disclosed stock portfolio, making it one of their key holdings.
Paul Tudor Jones's peak holding in Biogen Inc. (BIIB) was 125,668 shares, as reported at the end of Q3 2016.